Patisiran in hATTR Amyloidosis: Six-Month Latency Period before Efficacy

Hereditary amyloidosis associated with mutations in the transthyretin gene (hATTR) is a progressive devastating disease, with a fatal outcome occurring within 10years after onset. In recent years, TTR gene silencing therapy appeared as a promising therapeutic strategy, showing evidence that disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Gentile, Luca, Russo, Massimo, Luigetti, Marco, Bisogni, Giulia, Di Paolantonio, Andrea, Romano, Angela, Guglielmino, Valeria, Arimatea, Ilenia, Sabatelli, Mario, Toscano, Antonio, Vita, Giuseppe, Mazzeo, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073153/
https://www.ncbi.nlm.nih.gov/pubmed/33921571
http://dx.doi.org/10.3390/brainsci11040515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073153/
https://www.ncbi.nlm.nih.gov/pubmed/33921571
http://dx.doi.org/10.3390/brainsci11040515

Ejemplares similares